Ono 3307 Free Base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414580

CAS#: 76472-28-1 (free base)

Description: Ono 3307 Free Base is a new synthetic protease inhibitor


Chemical Structure

img
Ono 3307 Free Base
CAS# 76472-28-1 (free base)

Theoretical Analysis

MedKoo Cat#: 414580
Name: Ono 3307 Free Base
CAS#: 76472-28-1 (free base)
Chemical Formula: C14H14N4O4S
Exact Mass: 334.0736
Molecular Weight: 334.35
Elemental Analysis: C, 50.29; H, 4.22; N, 16.76; O, 19.14; S, 9.59

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 76472-29-2 (mesylate); 76472-28-1 (free base)  

Synonym: Ono 3307 Free Base; Ono3307; Ono-3307

IUPAC/Chemical Name: Benzoic acid, 4-((aminoiminomethyl)amino)-, 4-(aminosulfonyl)phenyl ester

InChi Key: YFUQTMNUQVFBBS-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H14N4O4S/c15-14(16)18-10-3-1-9(2-4-10)13(19)22-11-5-7-12(8-6-11)23(17,20)21/h1-8H,(H4,15,16,18)(H2,17,20,21)

SMILES Code: O=C(OC1=CC=C(S(=O)(N)=O)C=C1)C2=CC=C(NC(N)=N)C=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 334.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Matsuoka S, Futagami M, Ohno H, Imaki K, Okegawa T, Kawasaki A. Inhibitory effects of ONO-3307 on various proteases and tissue thromboplastin in vitro and on experimental thrombosis in vivo. Jpn J Pharmacol. 1989 Dec;51(4):455-63. doi: 10.1254/jjp.51.455. PMID: 2515329.

2: Hirano T, Manabe T, Tobe T. Impaired hepatic energy metabolism in rat acute pancreatitis: protective effects of prostaglandin E2 and synthetic protease inhibitor ONO 3307. J Surg Res. 1992 Sep;53(3):238-44. doi: 10.1016/0022-4804(92)90041-w. PMID: 1528049.

3: Hirano T, Manabe T, Calne R, Tobe T. Effects of acute pancreatitis on hepatic secretion of lysosomal enzymes into bile and hepatic lysosomal fragility: protective effects of a new synthetic protease inhibitor, ONO 3307. Scand J Gastroenterol. 1992;27(3):227-32. doi: 10.3109/00365529208999954. PMID: 1502486.

4: Yoshikawa T, Takeda S, Naito Y, Kondo M. Protective effects of ONO-3307, a new synthetic protease inhibitor against experimental disseminated intravascular coagulation in rats. Thromb Res. 1990 Oct 1;60(1):1-7. doi: 10.1016/0049-3848(90)90334-9. PMID: 2278034.

5: Hirano T, Manabe T, Ohshio G, Nio Y. Protective effects of combined therapy with a protease inhibitor, ONO 3307, and a xanthine oxidase inhibitor, allopurinol on temporary ischaemic model of pancreatitis in rats. Nihon Geka Hokan. 1992 May 1;61(3):224-33. PMID: 1444702.

6: Sobajima H, Hayakawa T, Kondo T, Shibata T, Kitagawa M, Sakai Y, Ishiguro H, Tanikawa M, Nakae Y. Effect of a new synthetic trypsin inhibitor on taurocholate-induced acute pancreatitis in rats. Pancreas. 1993 Mar;8(2):240-7. doi: 10.1097/00006676-199303000-00016. PMID: 8460097.

7: Hirano T, Manabe T, Tobe T. Protection by a new synthetic protease inhibitor, ONO3307, of the rat exocrine pancreas during acute edematous pancreatitis induced by a supramaximal dose of caerulein in comparison with FOY007. Pharmacology. 1992;45(2):107-16. doi: 10.1159/000138986. PMID: 1381836.

8: Hirano T, Yotsumoto TM, Ando K, Tobe T. [Changes of acinar cells in the pancreato-biliary duct ligation with exocrine pancreatic stimulation model in rats; protective effects of a new potent protease inhibitor, ONO3307]. Nihon Geka Hokan. 1991 Sep 1;60(5):342-53. Japanese. PMID: 1726453.

9: Hirano T, Manabe T, Tobe T. Cytoprotective effects of prostaglandins and a new potent protease inhibitor in acute pancreatitis. Am J Med Sci. 1992 Sep;304(3):154-63. doi: 10.1097/00000441-199209000-00003. PMID: 1282294.

10: Ono S, Tamakuma S, Mochizuki H, Kinoshita M, Ohkusa Y, Aosasa S, Oda Y, Ohe H. Clinical and experimental studies on the role of platelet-activating factor (PAF) in the pathogenesis of septic DIC. Surg Today. 1993;23(3):228-33. doi: 10.1007/BF00309232. PMID: 8467174.